ReviewHandbook of experimental pharmacology2025
Glycosylation in Stem Cell Biology.
Review in Handbook of experimental pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The N-Glycome to Differentiate Mesenchymal Stem Cells Upon Chondrogenic Differentiation, Dedifferentiation, and Senescence.Proteomics · 2026Article
- Glycan-related genes and genetic disorders.Journal of human genetics · 2026Review
- Enzymatic glycosylation as a potential molecular link between Alzheimer's disease and glaucoma.International journal of ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Embryonic stem cells are pluripotent stem cells originally derived from the inner cell mass of blastocysts and have the essential characteristics of pluripotency and self-renewal. Pluripotent stem cells can differentiate into all of the cell types constituting the adult body. Our current understanding is that pluripotent stem cells transition through three stages: a naïve state, a formative state, and a primed state. The stemness and differentiation of pluripotent stem cells depend on cell-surface glycans, which work as essential modulators in ligand-receptor interactions, cell-cell interactions, and cell-extracellular matrix interactions. Cell-surface glycans bind to various signal ligands, including Wnt, fibroblast growth factors, and bone morphogenetic proteins, and are tissue-specific and developmentally regulated. In addition, intracellular O-linked N-acetylglucosamine, a modification found on only nuclear or cytoplasmic proteins, regulates core transcription factors involved in stemness, phosphorylation of downstream signal components, epigenetics, and liquid-liquid phase separation. Thus, various kinds of glycans regulate each stem cell status; furthermore, different glycan structures at each stage are simultaneously epigenetically regulated by the polycomb repressive complex PRC2. Understanding the functions of glycans in stemness and differentiation is increasingly important for both innovative clinical applications and basic research. This chapter focuses on the roles of glycans in mouse and human pluripotent stem cells.
Indexed as
Identifiers
40323418What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.